Catalyst
Slingshot members are tracking this event:
ProQR Receives Fast Track Designation from FDA for QR-010 for Cystic Fibrosis
Do you think this event is important to the companies below? How will it affect their stock price?
Related Companies | Importance
|
Impact on Stocks
|
||||
---|---|---|---|---|---|---|
PRQR |
|
|
Additional Information
“We are very pleased with the Fast Track designation the FDA granted us for QR-010. It highlights the unmet medical need in cystic fibrosis and the need for innovative and more efficacious medicines for CF. We look forward to working with the FDA to bring QR-010 to patients faster,” said Daniel de Boer, Chief Executive Officer of ProQR. “We are also looking forward to releasing data for the first-in-human trials of QR-010 in CF patients later this year during the North American CF conference (NACFC) held on 27-29 October 2016 in Orlando, Florida.”
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 19, 2016
Related Projects
- Exploring the potential of ProQR Therapeutics' (PRQR) Cystic Fibrosis drug QR-010 after its Proof-Of-Concept Trial PRQR, VRTX, GLPG Executed On: Jul 31, 2017 at 10:00 AM EDT
Related Keywords
Fast Track Designation, Qr-010, Cystic Fibrosis, Cf Due To The ∆f508 Mutation